Relato de caso – eventos neuromusculares relacionados com inibidores de checkpoint
DOI:
https://doi.org/10.34024/rnc.2022.v30.12780Palavras-chave:
Miastenia gravis, miopatia, neuropatia, imunoterapia, anti-pd1, melanoma, neoplasia, câncerResumo
O melanoma invasivo possui alta mortalidade e sua incidência tem aumentado nos últimos anos de forma considerável. A descoberta dos inibidores de checkpoint (ICP), melhorou significativamente o prognóstico do tratamento, aumentando sobrevida e qualidade de vida dos pacientes com essas neoplasias. Embora a eficácia comprovada desses tratamentos tenha mudado a história natural do melanoma, vários efeitos colaterais foram relatados, principalmente relacionados ao sistema imunológico. O objetivo desse estudo é descrever um caso de eventos neuromusculares sobrepostos de miopatia, miastenia gravis e neuropatia periférica após início de tratamento com anti-PD1 (Nivolumab) em um paciente com melanoma invasivo.
Métricas
Referências
Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, et al. Melanoma. Lancet 2018;392:971-84. https://doi.org/10.1016/S0140-6736(18)31559-9
Herrscher H, Robert C. Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting. Curr Opin Oncol 2020;32:106-13. https://doi.org/10.1097/cco.0000000000000610
Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 2016;29:806-12.
https://doi.org/10.1097/wco.0000000000000391
Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol 2018;4:1721-8. https://doi.org/10.1001/jamaoncol.2018.3923
Kao JC, Brickshawana A, Liewluck T. Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors. Curr Neurol Neurosci Rep 2018;18:63. https://doi.org/10.1007/s11910-018-0878-7
Johansen A, Christensen SJ, Scheie D, Højgaard JLS, Kondziella D. Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review. Neurology 2019;92:663-74. https://doi.org/10.1212/wnl.0000000000007235
Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, et al. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncol 2016;2:234-40. https://doi.org/10.1001/jamaoncol.2015.4368
Touat M, Maisonobe T, Knauss S, Hadj B, Salem O, Hervier B, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 2018;91:e985-94. https://doi.org/10.1212/wnl.0000000000006124
Anquetil C, Salem JE, Lebrun-Vignes B, Johnson DB, Mammen AL, Stenzel W, et al. Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution. Circulation 2018;138:743-5. https://doi.org/10.1161/circulationaha.118.035898
Shah M, Tayar JH, Abdel-Wahab N, Suarez-Almazor ME. Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Semin Arthritis Rheum 2019;48:736-40. https://doi.org/10.1016/j.semarthrit.2018.05.006
Seki M, Uruha A, Ohnuki Y, Kamada S, Noda T, Onda A, et al. Inflammatory myopathy associated with PD-1 inhibitors. J Autoimmun 2019;100:105-13.
https://doi.org/10.1016/j.jaut.2019.03.005
Moreira A, Loquai C, Pföhler C, Kähler KC, Knauss S, Heppt MV, et al. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer 2019;106:12-23. https://doi.org/10.1016/j.ejca.2018.09.033
Makarious D, Horwood K, Coward JIG. Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors. Eur J Cancer 2017;82:128-36. https://doi.org/10.1016/j.ejca.2017.05.041
Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 2017;89:1127-34. https://doi.org/10.1212/wnl.0000000000004359
Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res 2019;115:854-68. https://doi.org/10.1093/cvr/cvz026
Chen X, Haggiagi A, Tzatha E, DeAngelis LM, Santomasso B. Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy. Clin Neurophysiol 2019;130:1440-5. https://doi.org/10.1016/j.clinph.2019.03.035
Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017;5:95. https://doi.org/10.1186/s40425-017-0300-z
Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018;36:1714-68.
https://doi.org/10.1200/jco.2017.77.6385
Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. Management of Immunotherapy-Related Toxicities, Version 1.2019. J Natl Compr Canc Netw 2019;17:255-89. https://doi.org/10.6004/jnccn.2019.0013
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2022 Mariana Queiroz Borges, Ellen Camila Rodrigues Dias , Zeno Augusto de Sousa Neto, Mariana Resende Guedes, Ábner Pereira Prado, Marcos Alexandre Diniz Carneiro
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Como Citar
Aprovado 2021-12-06
Publicado 2022-01-25
